Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10127)	5/20/1999 11:31:00 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

TAIPAN TAIPAN TAIPAN HOTLINE!!!!!!!!!!!!!!! It was titled BACK FROM THE DEAD Some points made, "Xoma has Fast Track approval status for Neuprex for the lead indication, so it will get an accelerated review from the FDA." "While the FDA approval process is difficult to time, it is feasible that Xoma will have Neuprex on the market in early 2000." "If Neuprex is approved by the FDA, it will be the only drug on the market for septic-related illnesses -- potentially a five billion dollar global market." "Xoma's ratio of R&D spending to SG&A overhead is high by biotech industry standards -- a testimony to the world class character of CEO Jack Castello." When speaking of Oppenheimer "The new coverage has already added liquidity to the stock." Last but not least "institutions are beginning to build up positions" Taipan anyone? www.taipanonline.com